Current Oncology Reports

, Volume 14, Issue 2, pp 97–104

RET TKI: Potential Role in Thyroid Cancers

Authors

    • Department of Internal MedicineUniversity of Pisa, School of Medicine
  • Poupak Fallahi
    • Department of Internal MedicineUniversity of Pisa, School of Medicine
  • Silvia Martina Ferrari
    • Department of Internal MedicineUniversity of Pisa, School of Medicine
  • Caterina Mancusi
    • Department of Internal MedicineUniversity of Pisa, School of Medicine
  • Michele Colaci
    • Rheumatology Unit, Department of Internal MedicineUniversity of Modena & Reggio E.
  • Libero Santarpia
    • Translational Research Unit, Department of OncologyHospital of Prato and Istituto Toscana Tumori
  • Clodoveo Ferri
    • Rheumatology Unit, Department of Internal MedicineUniversity of Modena & Reggio E.
Evolving Therapies (RM Bukowski, Section Editor)

DOI: 10.1007/s11912-012-0217-0

Cite this article as:
Antonelli, A., Fallahi, P., Ferrari, S.M. et al. Curr Oncol Rep (2012) 14: 97. doi:10.1007/s11912-012-0217-0

Abstract

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.

Keywords

Papillary thyroid cancerMedullary thyroid cancerTargeted molecular therapiesTyrosine kinase inhibitorsRETVEGFR

Copyright information

© Springer Science+Business Media, LLC 2012